A multicentre, randomized, open label clinical trial for the safety evaluation of a short dose escalation scheme using one strength for allergen immunotherapy with an aluminium-hydroxide adsorbed native allergen preparation of house dust mite allergens in adult and adolescent patients with moderate to severe allergic rhinitis or rhinoconjunctivitis with or without asthma
Latest Information Update: 21 Dec 2022
At a glance
- Drugs House dust mite allergy immunotherapy (Primary)
- Indications Allergic rhinitis; Allergic rhinoconjunctivitis
- Focus Adverse reactions
- Acronyms TiME
- Sponsors Allergopharma
- 19 Dec 2022 Status changed from recruiting to completed.
- 01 Jun 2022 Planned End Date changed to 4 Feb 2023.
- 30 Apr 2021 New trial record